B
Benjamin Weide
Researcher at University of Tübingen
Publications - 132
Citations - 10305
Benjamin Weide is an academic researcher from University of Tübingen. The author has contributed to research in topics: Melanoma & Antigen. The author has an hindex of 39, co-authored 129 publications receiving 7891 citations. Previous affiliations of Benjamin Weide include German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen,Eliezer M. Van Allen,Diana Miao,Diana Miao,Bastian Schilling,Sachet A. Shukla,Sachet A. Shukla,Christian U. Blank,Lisa Zimmer,Antje Sucker,Uwe Hillen,Marnix H Geukes Foppen,Simone M. Goldinger,Jochen Utikal,Jochen Utikal,Jessica C. Hassel,Benjamin Weide,Katharina C. Kaehler,Carmen Loquai,Peter Mohr,Ralf Gutzmer,Reinhard Dummer,Stacey Gabriel,Catherine J. Wu,Catherine J. Wu,Dirk Schadendorf,Levi A. Garraway,Levi A. Garraway +27 more
TL;DR: Investigating the roles of tumor-specific neoantigens and alterations in the tumor microenvironment in the response to ipilimumab found no recurrent neoantigen peptide sequences predicted responder patient populations, suggesting detailed integrated molecular characterization of large patient cohorts may be needed to identify robust determinants of response and resistance to immune checkpoint inhibitors.
Journal ArticleDOI
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Eliezer M. Van Allen,Eliezer M. Van Allen,Nikhil Wagle,Nikhil Wagle,Antje Sucker,Daniel J. Treacy,Cory M. Johannessen,Eva M. Goetz,Chelsea S. Place,Chelsea S. Place,Amaro Taylor-Weiner,Steven R. Whittaker,Gregory V. Kryukov,Eran Hodis,Eran Hodis,Eran Hodis,Mara Rosenberg,Aaron McKenna,Aaron McKenna,Kristian Cibulskis,Deborah N. Farlow,Lisa Zimmer,Uwe Hillen,Ralf Gutzmer,Simone M. Goldinger,Selma Ugurel,Helen Gogas,Friederike Egberts,Carola Berking,Uwe Trefzer,Carmen Loquai,Benjamin Weide,Jessica C. Hassel,Stacey Gabriel,Scott L. Carter,Gad Getz,Gad Getz,Levi A. Garraway,Levi A. Garraway,Levi A. Garraway,Dirk Schadendorf +40 more
TL;DR: A "long tail" of new mitogen-activated protein kinase (MAPK) pathway alterations (MAP2K2, MITF) that confer RAF inhibitor resistance are discovered that may model subsequent resistance studies of BRAF(V600)-mutant melanoma.
Journal ArticleDOI
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
Emanuela Romano,Monika Kusio-Kobialka,Periklis G. Foukas,Petra Baumgaertner,Christiane Meyer,Pierluigi Ballabeni,Olivier Michielin,Benjamin Weide,Pedro Romero,Daniel E. Speiser +9 more
TL;DR: It is shown, to the knowledge for the first time, that ipilimumab can engage ex vivo FcγRIIIA (CD16)-expressing, nonclassical monocytes resulting in ADCC-mediated lysis of regulatory T cells (Tregs).
Journal ArticleDOI
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.
Benjamin Weide,Alexander Martens,Jessica C. Hassel,Carola Berking,Michael A. Postow,Michael A. Postow,Kees Bisschop,Ester Simeone,J. Mangana,Bastian Schilling,Anna Maria Di Giacomo,Nicole Brenner,Katharina C. Kähler,Lucie Heinzerling,Ralf Gutzmer,Armin Bender,Christoffer Gebhardt,Christoffer Gebhardt,Emanuela Romano,Friedegund Meier,Peter Martus,Michele Maio,Christian U. Blank,Dirk Schadendorf,Reinhard Dummer,Paolo A. Ascierto,Geke A. P. Hospers,Claus Garbe,Jedd D. Wolchok,Jedd D. Wolchok +29 more
TL;DR: High REC and RLC, low LDH, and absence of metastasis other than soft-tissue/lung are independent baseline characteristics associated with favorable OS of patients with melanoma treated with pembrolizumab, indicating a subgroup with excellent prognosis.
Journal ArticleDOI
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
Alexander Martens,Kilian Wistuba-Hamprecht,Marnix H Geukes Foppen,Jianda Yuan,Michael A. Postow,Phillip Wong,Emanuela Romano,Amir Khammari,Brigitte Dréno,Mariaelena Capone,Paolo A. Ascierto,Anna Maria Di Giacomo,Michele Maio,Bastian Schilling,Antje Sucker,Dirk Schadendorf,Jessica C. Hassel,Thomas Eigentler,Peter Martus,Jedd D. Wolchok,Christian U. Blank,Graham Pawelec,Claus Garbe,Benjamin Weide +23 more
TL;DR: A baseline signature of low LDH, AMC, and MDSCs as well as high AEC, Tregs, and RLC is associated with favorable outcome following ipilimumab.